Kazia Therapeutics (KZIA) EBITDA (2009 - 2016)

Kazia Therapeutics' (KZIA) quarterly EBITDA came in at -$3.2 million in Q4 2016, up 72.0% on a QoQ basis from -$11.4 million in Q4 2012.

Kazia Therapeutics (KZIA) EBITDA (2009 - 2016) Analysis & Trends

Kazia Therapeutics (KZIA) has 5 years of EBITDA data on file, last reported at -$3.2 million in Q4 2016.

Quarterly EBITDA changed N/A year-over-year to -$3.2 million in Q4 2016, while the trailing twelve-month figure through Dec 2016 was -$20.7 million (changed N/A YoY) and the FY2025 annual result came in at -$14.4 million, up 19.35% from the prior year.
EBITDA rose to -$3.2 million in Q4 2016, from -$11.4 million in the prior quarter.
In the past five years, EBITDA ranged from a high of -$3.2 million in Q4 2016 to a low of -$11.4 million in Q4 2012.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	1.25 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	1.29 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	493.00 Mn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-505.13 Mn
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	325.05 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-2.33 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	133.12 Mn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	231.44 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-1.55 Mn
10	Kazia Therapeutics	4.22 Bn	4.22 Bn	-	-

Download Data